Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allurion Technologies, Inc. Common Stock (NY:ALUR)

2.650 +0.290 (+12.29%)
Streaming Delayed Price Updated: 11:28 AM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allurion Technologies, Inc. Common Stock

< Previous 1 2 3 Next >
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Report First Quarter 2025 Financial Results on May 14, 2025
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Postponement of Special Meeting of Stockholders
From Allurion Technologies, Inc.
Via Business Wire
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Participate in Upcoming Investor Conferences
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
From Allurion Technologies, Inc.
Via Business Wire
Allurion Relaunches in France
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Positive Topline Results From AUDACITY Trial
From Allurion Technologies, Inc.
Via Business Wire
Allurion Technologies, Inc. Announces Reverse Stock Split
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
From Allurion Technologies, Inc.
Via Business Wire
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
From Allurion Technologies, Inc.
Via Business Wire
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
Penny stocks are a risky but potentially rewarding opportunity for investors willing to take on their uncertainty; these stocks may stand out from the pack. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Allurion Receives Continued Listing Standards Notice from NYSE
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
From Allurion Technologies, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.